Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Pfizer (PFE) PT Raised to $30 at Citi
August 13, 2024 4:41 PM EDTCiti analyst Andrew Baum raised the price target on Pfizer (NYSE: PFE) to $30.00 (from $28.00) while maintaining a Neutral rating.
The analyst comments "We update our forecasts post 2Q24 to incorporate latest results and guidance, and sales, prescription, and currency trends. Our 2024E non-GAAP EPS... More
